Proprotein Convertase 9
-
Subject Areas on Research
- 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
- 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
- A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
- Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis.
- Association of Prior Authorization and Out-of-pocket Costs With Patient Access to PCSK9 Inhibitor Therapy.
- Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients.
- Deep thoughts on lipids and cognition.
- Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES.
- Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.
- Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis.
- Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study.
- Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher.
- Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial.
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
- Exploration of PCSK9 as a Cardiovascular Risk Factor: Is There a Link to the Platelet?
- From the editor: A run of success in treating atherosclerotic vascular disease.
- Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice: An NCDR Research to Practice (R2P) project.
- Malaria severity: Possible influence of the E670G PCSK9 polymorphism: A preliminary case-control study in Malian children.
- PCSK9 Loss-of-Function Variants, Low-Density Lipoprotein Cholesterol, and Risk of Coronary Heart Disease and Stroke: Data From 9 Studies of Blacks and Whites.
- PCSK9 inhibitors for prevention of atherosclerotic cardiovascular disease.
- Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome: A Narrative Review.
- RNA-guided transcriptional silencing in vivo with S. aureus CRISPR-Cas9 repressors.
- Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes.
- Role of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with coronary artery disease undergoing percutaneous coronary intervention.
- Specialty Pharmaceuticals for Hyperlipidemia--Impact on Insurance Premiums.
- Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia.
- The economics of PCSK-9 inhibitors.
- Therapy and clinical trials.
- Trans-ethnic fine-mapping of lipid loci identifies population-specific signals and allelic heterogeneity that increases the trait variance explained.